1. Figure 2. Immunophenotypic characteristics of Gal-4-treated monocytes
Figure 2. Immunophenotypic characteristics of Gal-4-treated monocytes. (A-C) Human PBMCs were treated with Gal-4 (10 µg/ml) or LPS (1 µg/ml) for 24 h. (A) Expression levels of CCR1, CCR2, CXCR4, and CCR5 on CD14+ monocytes were analyzed by flow cytometry. (B) Expression levels of TLR1, TLR2, and TLR4 on the CD14+ monocytes were analyzed by flow cytometry. (C) Bars show expression levels of CD80, CD86, CD40, and HLA-DR on CD14+ monocytes. (A, C) Each value is mean±standard deviation of 3 independent experiments. (B) Data are representative results of 3 independent experiments.*p<0.05; **p<0.01.
Figure 2. Immunophenotypic characteristics of Gal-4-treated monocytes. (A-C) Human PBMCs were treated with Gal-4 (10 µg/ml) or LPS (1 µg/ml) for 24 h. (A) Expression levels of CCR1, CCR2, CXCR4, and CCR5 on CD14+ monocytes were analyzed by flow cytometry. (B) Expression…
Immune Netw Jun;19(3):e17.